×
About 56,305 results

ALLMedicine™ Hepatocellular Carcinoma Center

Research & Reviews  21,049 results

EGFR Inhibitors Synergize with Lenvatinib for Liver Cancer Treatment.
https://doi.org/10.1158/2159-8290.CD-RW2021-108
Cancer Discovery;

Aug 1st, 2021 - EGFR inhibition and lenvatinib exhibit synthetic lethality in hepatocellular carcinoma.

Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.
https://doi.org/10.1002/cam4.4162
Cancer Medicine; Zhang C, Feng S et. al.

Aug 1st, 2021 - Sarcomatoid hepatocellular carcinoma (HCC) is a rare and highly lethal histological subtype of HCC, with completely unknown genetic etiology and therapeutic targets. We included 16 patients with sarcomatoid HCC receiving radical resection among 67...

Pure laparoscopic living donor liver transplantation: Dreams come true.
https://doi.org/10.1111/ajt.16782
American Journal of Transplantation : Official Journal Of... Suh KS, Hong SK et. al.

Aug 1st, 2021 - Minimally invasive approaches are increasingly being applied in surgeries and have recently been used in living donor hepatectomy. We have developed a safe and reproducible method for minimally invasive living donor liver transplantation, which co...

Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United Stat...
https://doi.org/10.1016/j.cgh.2021.07.036
Clinical Gastroenterology and Hepatology : the Official C... Martin P, Nguyen MH et. al.

Jul 31st, 2021 - Chronic hepatitis B (CHB) infection remains the most frequent etiology of hepatocellular carcinoma globally as well as a major cause of cirrhosis. Despite vaccination, substantial numbers of persons have already been infected with hepatitis B viru...

Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311534
World Journal of Gastroenterology; Shi YW, Yang RX et. al.

Jul 31st, 2021 - With the increasing incidence of obesity and metabolic syndrome worldwide, concomitant nonalcoholic fatty liver disease (NAFLD) in patients with chronic hepatitis B (CHB) has become highly prevalent. The risk of dual etiologies, outcome, and mecha...

see more →

Guidelines  24 results

Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis,...
https://doi.org/10.1016/j.clinre.2020.101590
Clinics and Research in Hepatology and Gastroenterology; Blanc JF, Debaillon-Vesque A et. al.

Mar 30th, 2021 - This document is a summary of the French Intergroup guidelines regarding the management of hepatocellular carcinoma (HCC) published in March 2019. It is a collaborative work under the auspices of most of the French medical societies involved in th...

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achie...
https://doi.org/10.1053/j.gastro.2020.11.051
Gastroenterology Younossi ZM, Corey KE et. al.

Dec 12th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, h...

Latin American Association for the study of the liver (ALEH) practice guidance for the ...
https://doi.org/10.1016/j.aohep.2020.09.006
Annals of Hepatology; Arab JP, Dirchwolf M et. al.

Oct 9th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with...
https://doi.org/10.1016/j.annonc.2019.12.001
Annals of Oncology : Official Journal of the European Soc... Chen LT, Martinelli E et. al.

Feb 19th, 2020 - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, tre...

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  739 results

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
https://clinicaltrials.gov/ct2/show/NCT03289273

May 6th, 2020 - Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02460835

May 1st, 2020 - This is a pilot single arm study with the primary endpoints of feasibility and preliminary estimates of safety and efficacy. This protocol builds on over 25 years of experience with high dose liver RT (Radiation Therapy), and in particular adaptiv...

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT03203304

Apr 29th, 2020 - 1.1 Primary Objective & Hypothesis Determine the safety and tolerability of SBRT followed by nivolumab or ipilimumab with nivolumab for hepatocellular carcinoma by establishing the rates of toxicity that occur within 6 months from start of SBRT. H...

Oral Microbiome of Patients With Hepatitis C Virus Infection
https://clinicaltrials.gov/ct2/show/NCT03682549

Apr 24th, 2020 - Human oral cavity is a great habitat for more than 600 species of bacteria, known as oral microbiota, living in equilibrium. Oral microbiota plays an important role in maintaining oral health; however when the balance in oral bacterial population ...

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02423343

Apr 24th, 2020 - The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or refractory non-sma...

see more →

News  689 results

Study Supports Chemopreventive Effect of Statins on Liver Cancer in NASH Cirrhosis
https://www.medscape.com/viewarticle/954877

Jul 20th, 2021 - NEW YORK (Reuters Health) - New research provides supporting evidence for chemopreventive effects of statins on hepatocellular carcinoma (HCC) in patients with nonalcoholic steatohepatitis (NASH) cirrhosis. In the American Journal of Gastroenterol...

Good Survival, Outcomes With TARE for HCC
https://www.medscape.com/viewarticle/954970

Jul 19th, 2021 - Patients with hepatocellular carcinoma (HCC) can be offered transarterial radioembolization (TARE) as a safe and effective first-line treatment or adjunct to other locoregional therapies, authors of a large multicenter study reported. Among 422 pa...

Donafenib Yields Survival Advantage Over Sorafenib in Chinese Patients With Advanced Liver Cancer
https://www.medscape.com/viewarticle/954780

Jul 15th, 2021 - NEW YORK (Reuters Health) - Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, significantly improved overall survival versus sorafenib in first-line treatment of patients with advanced hepatocellular carcinoma (HCC) i...

Protein Expression May Predict HBV DNA Suppression
https://www.medscape.com/viewarticle/954484

Jul 8th, 2021 - Stopping nucleoside analog therapy in patients with hepatitis B viral (HBV) infections results in sustained viral suppression in only a minority of patients, but a new study suggests there are immune signatures that may serve as predictive biomark...

Tislelizumab Benefit in HCC Undimmed by Prior Therapies
https://www.medscape.com/viewarticle/954239

Jul 6th, 2021 - With the novel immunotherapy tislelizumab, durable responses are achieved for patients with advanced hepatocellular carcinoma (HCC), regardless of the number of prior lines of therapy, show results from a phase 2, open-label trial. RATIONALE 208 i...

see more →

Patient Education  4 results see all →